All In Biotech

Drug Trial Radar · NCT04166058

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

A Phase 3, Open-label, Long-term Safety Study of Oral Linaclotide Administered to Pediatric Participants With Functional Constipation (FC) or Irritable Bowel Syndrome With Constipation (IBS-C)

Last checked: Nov 20, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

381

Actual

Start

Nov 19, 2019

Primary completion

Jun 5, 2025

Study completion Jun 5, 2025

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
Collaborators
Ironwood Pharmaceuticals, Inc.
First posted
Nov 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation participants) of linaclotide exposure that will enroll pediatric participants (6-17 years of age) with FC or IBS-C who completed study intervention in studies LIN-MD-62, LIN-MD-63, or LIN-MD-64 based on the individual study criteria.

Conditions

  • Irritable Bowel Syndrome With Constipation
  • Functional Constipation

Interventions

  • Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers)Drug

    Participants who completed study LIN-MD-63 at their time of enrollment will be assigned a dose of 290 μg. Participants who received ≤ 145 μg linaclotide or placebo in study LIN-MD-63 at the time of completion will continue to receive 145 μg. Participants who completed study LIN-MD-64 at their time of enrollment will be assigned a dose of 290 μg if they choose to receive open-label or continue to receive blinded dose of 145 or 290 μg if they choose to remain on the same blinded dose.

  • Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)Drug

    Participants whom are between the ages of 6-11 years old at their time of enrollment will be assigned a dose of 72 μg. Participants whom are between the ages of 12-17 years old at their time of enrollment will be randomized at 1:1 ratio to 72 or 145 μg linaclotide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs).Time frame: From first dose of study drug until 30 days following last dose of study drug [up to 24 weeks (FC participants) or 52 weeks (IBS-C participants)].

Locations

72 sites in 4 countries. Site status is shown where the registry gives one.

  • Central Research Associates /ID# 237953

    Birmingham, Alabama

  • G & L Research, LLC /ID# 238093

    Foley, Alabama

  • The Center for Clinical Trials Inc. /ID# 234605

    Saraland, Alabama

  • HealthStar Research of Hot Springs PLLC /ID# 234608

    Hot Springs, Arkansas

  • Preferred Research Partners /ID# 237109

    Little Rock, Arkansas

  • Applied Research Center of Arkansas /ID# 238069

    Little Rock, Arkansas

  • Advanced Research Center /ID# 237960

    Anaheim, California

  • Kindred Medical Institute, LLC /ID# 237367

    Corona, California

  • Duplicate_Center for Clinical Trials LLC /ID# 234629

    Paramount, California

  • Medical Ctr for Clin Research /ID# 236911

    San Diego, California

  • Lynn Institute of Denver /ID# 238086

    Aurora, Colorado

  • Childrens National Medical Center /ID# 234417

    Washington D.C., District of Columbia

  • Prohealth Research Center /ID# 234659

    Doral, Florida

  • Dolphin Medical Research /ID# 234676

    Doral, Florida

  • Amedica Research Institute Inc /ID# 234666

    Hialeah, Florida

  • Nemours Childrens Specialty Care /ID# 237991

    Jacksonville, Florida

  • Elite Clinical Research /ID# 234651

    Miami, Florida

  • My Preferred Research LLC /ID# 237943

    Miami, Florida

  • South Miami Medical & Research Group Inc. /ID# 234654

    Miami, Florida

  • Valencia Medical & Research Center /ID# 234671

    Miami, Florida

  • Advanced Research for Health Improvement /ID# 238253

    Naples, Florida

  • Pediatric & Adult Research Center /ID# 234681

    Orlando, Florida

  • Nemours Children's Hospital /ID# 234429

    Orlando, Florida

  • Oviedo Medical Research /ID# 234692

    Oviedo, Florida

  • Treken Primary Care /ID# 234645

    Atlanta, Georgia

  • Children's Healthcare of Atlanta - Ferry Rd /ID# 237005

    Atlanta, Georgia

  • Children's Ctr Digestive, US /ID# 237574

    Atlanta, Georgia

  • River Birch Research Alliance /ID# 237963

    Blue Ridge, Georgia

  • Clinical Research Institute /ID# 234702

    Stockbridge, Georgia

  • Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 236342

    Stockbridge, Georgia

  • KU Wichita Center for Clinical Research /ID# 234500

    Wichita, Kansas

  • Michael W. Simon, MD, PSC /ID# 236516

    Lexington, Kentucky

  • Virgo Carter Pediatrics /ID# 234518

    Silver Spring, Maryland

  • MNGI Digestive Health, P. A. /ID# 234437

    Minneapolis, Minnesota

  • GI associates and Endoscopy Ce /ID# 237969

    Flowood, Mississippi

  • David M. Headley, MD, P.A. /ID# 238216

    Port Gibson, Mississippi

  • Private Practice - Dr. Craig Spiegel /ID# 234545

    Bridgeton, Missouri

  • Medclinical Research Partners LLC/ Foundation Pediatrics /ID# 234566

    East Orange, New Jersey

  • University of New Mexico /ID# 236983

    Albuquerque, New Mexico

  • Columbia University Irving Medical Center /ID# 235686

    New York, New York

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.